Ozempic & HS: Biomarkers, Evidence & Compounded Alternatives

Last reviewed: May 16, 2026 Last updated: May 16, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) is not FDA-approved for hidradenitis suppurativa, but emerging clinical interest suggests GLP-1 receptor agonists may help reduce systemic inflammation and potentially improve symptoms in some HS patients. This mechanism is based on GLP-1's anti-inflammatory properties rather than direct skin-targeted action.

Hidradenitis suppurativa is a chronic inflammatory condition affecting apocrine glands, often driven by dysregulated immune responses and metabolic factors. Understanding whether GLP-1 therapy may support HS management requires evaluating individual biomarker patterns, genetic predispositions, and clinical context—not a one-size approach.

What HS Is and Why Inflammation Matters

Hidradenitis suppurativa involves recurrent, painful nodules and abscesses in skin folds. It is driven by follicular occlusion, bacterial colonization, and an overactive innate immune response. TNF-alpha and IL-17 are key inflammatory mediators implicated in HS pathogenesis.

Traditional HS treatments include biologics (TNF-alpha inhibitors, IL-17 inhibitors), antibiotics, and surgical intervention. Researchers are exploring whether systemic anti-inflammatory agents—including GLP-1 agonists—might address underlying inflammatory pathways and reduce flare frequency or severity.

GLP-1 Mechanism and HS: What Clinical Evidence Shows

GLP-1 receptor agonists activate GLP-1 receptors on immune cells and intestinal epithelial cells, reducing pro-inflammatory cytokine production and supporting intestinal barrier integrity. These mechanisms may theoretically benefit inflammatory skin conditions, though dedicated HS trials remain limited.

Evidence Category	Current Status
Dedicated HS RCTs with semaglutide	No large randomized controlled trials published; mostly case reports and observational data
Proposed mechanism in HS	Anti-inflammatory signaling via GLP-1R; potential reduction in TNF-alpha and IL-17
Patient populations studied	Mostly type 2 diabetes or obesity; HS-specific cohorts lacking
Timeline for potential benefit	Typically 8–12 weeks minimum; individual response highly variable

Biomarkers and Genetic Predisposition in HS Management

HS patients often show elevated inflammatory biomarkers including TNF-alpha, C-reactive protein (CRP), and IL-17. Identifying which patients may respond to GLP-1 therapy requires evaluating both systemic inflammation levels and individual genetic factors influencing immune regulation.

Genetic variants in GLP1R, GIPR, and other peptide pathway genes can influence how an individual's immune and metabolic systems respond to GLP-1 signaling. Understanding these predispositions may help clinicians and patients have more informed conversations about whether GLP-1 therapy is worth exploring alongside standard HS management.

Who Should Consider GLP-1 for HS: Provider-Guided Eligibility

GLP-1 therapy is not a first-line or approved HS treatment. Candidates may include HS patients with concurrent type 2 diabetes or obesity, elevated inflammatory biomarkers, inadequate response to biologic agents, or those seeking adjunctive anti-inflammatory support. Any consideration requires close provider oversight.

Patients should discuss HS severity, current treatment regimen, comorbidities, side effect tolerance, and whether HS-specific inflammatory biomarkers suggest potential benefit. A provider can assess whether GLP-1 represents a reasonable adjunctive option or whether standard biologics or other therapies remain the priority.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by revealing predispositions in peptide receptor pathways (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609) that influence how your body processes GLP-1 signaling and metabolic regulation. This information, combined with clinical biomarker data, can support a more informed conversation with your healthcare provider about whether compounded GLP-1 therapy might complement your HS management plan.

The genetic test does not predict exact medication response or guarantee HS improvement. Rather, it identifies genetic variants linked to variation in peptide pathway function. Interpreting these results with a qualified provider helps contextualize whether your genetic profile aligns with potential benefits of GLP-1 therapy, factoring in your individual inflammatory state and HS severity.

If you are exploring compounded GLP-1 options alongside HS management, PlexusDx can support a more personalized assessment through genetic testing and access to compounded semaglutide or tirzepatide formulations. All recommendations should be made in partnership with your dermatologist or HS specialist to ensure alignment with your overall treatment strategy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.